HOME >> MEDICINE >> NEWS
Possible new breast cancer gene

PHILADELPHIA -- Researchers at the Abramson Family Cancer Research Institute of the University of Pennsylvania and the Dana-Farber Cancer Institute describe in this weeks issue of Science a new candidate breast-cancer susceptibility gene. The Rap80 gene is required for the normal DNA-repair function of the well-known breast cancer gene BRCA1.

Cancer-causing mutations in the BRCA1 protein fail to bind to the Rap80 protein. Consequently BRCA1 is unable to identify DNA damage sites in the genome. When BRCA1 fails to fix DNA damage, cancer-causing mutations accumulate, spawning the development of breast and ovarian malignancies.

"With this current discovery, we have made significant new insights into the molecular mechanism by which BRCA1 recognizes sites of DNA damage that breast-cancer-causing mutated forms of BRCA1 cannot recognize," says co-senior author Roger Greenberg MD, PhD, Assistant Professor of Cancer Biology at Penn. "Now we have gained a partial understanding of the molecular basis between cancer-causing BRCA1 failures to fix DNA damage versus normal BRCA1s ability to fix DNA damage."

In this study, the researchers found Rap80 binds to the region of the BRCA1 protein that is necessary for recognizing sites of DNA damage. In the 1990s, investigators discovered that BRCA1 was involved in DNA repair by maintaining the normal number and structure of chromosomes. DNA breaks that aren't repaired can lead to cancer by increasing the rate of mutations, cancer-causing changes in the gene sequence.

More specifically, modification of proteins in the cell nucleus by another protein called ubiquitin that are tightly bound to DNA are responsible for signaling BRCA1 via Rap80 to action. Rap80 binds to specific types of ubiquitin that concentrate at DNA damage sites, enabling BRCA1 to be recruited to sites of damage.

BRCA1 and BRCA2 mutations account for less than 50 percent of inherited breast cancer. "The genetic b
'"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
24-May-2007


Page: 1 2

Related medicine news :

1. Possible predictors of relationship violence
2. Possible exposure to nerve agents and brain cancer deaths in Gulf War veterans
3. Possible treatment found for chemobrain
4. Survival differences by race most apparent in advanced stages of breast cancer
5. Regulator of lipid metabolism ensures high quality breast milk
6. MRI finds breast cancer before it becomes dangerous
7. New cause of tamoxifen resistance in breast cancer cells discovered at Lombardi
8. Pathway links inflammation, angiogenesis and breast cancer
9. Using MRI for diagnosis could help prevent breast cancer progression
10. Speeding up CT scans with cellphone technology, ultrasound warning signal for breast cancer
11. Fluorescence diffuse optical tomography provides high contrast, 3-D look at breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Possible new breast cancer gene

(Date:5/21/2013)... Today, Zane Benefits, Inc. published a ... accounts. Zane Benefits, which provides comprehensive and flexible alternatives ... in defined contribution and http://HRA ... to Zane Benefits’ website, the Affordable Care Act (known ... in 2010 and impacts many areas of health care ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Two executives ... Guidance (SBG) will identify which strategies can be most ... high-quality care to the members who are taking them, ... Services, Inc., “How to Manage Specialty Drugs to ... pharmaceuticals are now the main driver for rising prescription ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 While North ... synonymous with comprehensive travel guides. Brunswick Plantation & Golf ... packages that include access to 27 holes of "Top10" ... courses in North Carolina, knowing the Top 10 ... Lodges takes away the overwhelming task of selecting the ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Octo ... technology and management consulting solutions to the Federal ... Business Development. In the newly created role, ... all aspects of the firm’s business development function ... proposal management functions, and leading strategies to achieve ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) ... therapy for patients having severe bouts of chronic obstructive ... days of glucocorticoid treatment with prednisone to treat COPD ... but with fewer chances for adverse side effects, they ... period of treatment was not less effective than 14 ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Consulting Firm Execs to Discuss Strategies for Effective Management of Specialty Drugs in AIS’s May 30 Webinar 2Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2Health News:COPD Patients May Do Fine With Shorter Course of Steroids 2Health News:COPD Patients May Do Fine With Shorter Course of Steroids 3
(Date:5/21/2013)... and TARRYTOWN, N.Y. , May 21, ... and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that ... online the positive Phase 2a study results of dupilumab ... an investigational monoclonal antibody targeting the alpha subunit of ... of both IL-4 and IL-13, drivers of Th2 (Type ...
(Date:5/21/2013)... Calif. , May 21, 2013 Abaxis, ... blood analysis systems, announced today that Martin ... at the Stifel Annual Dental & Veterinary Conference on ... conference will be held at Le Parker Meridien Hotel ... About Abaxis Abaxis develops, manufactures, markets ...
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Medical Devices in the US Market ... Changing Regulatory and Reimbursement Scenario for ...   Summary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
Cached News: